Aegerion Pharmaceuticals Reaches New 12-Month Low at $29.45 (AEGR)
Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) hit a new 52-week low on Monday , AnalystRatingsNetwork.com reports. The company traded as low as $29.45 and last traded at $29.91, with a volume of 976,096 shares. The stock had previously closed at $32.85.
A number of research firms have recently commented on AEGR. Analysts at Goldman Sachs initiated coverage on shares of Aegerion Pharmaceuticals in a research note on Tuesday, May 27th. They set a “sell” rating and a $27.00 price target on the stock. Separately, analysts at Citigroup Inc. downgraded shares of Aegerion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 7th. Finally, analysts at Deutsche Bank cut their price target on shares of Aegerion Pharmaceuticals from $115.00 to $70.00 in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $77.71.
The stock has a 50-day moving average of $38.20 and a 200-day moving average of $55.47. The company’s market cap is $896.3 million.
Aegerion Pharmaceuticals (NASDAQ:AEGR) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.25) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.35) by $0.10. The company had revenue of $27.00 million for the quarter, compared to the consensus estimate of $33.58 million. Analysts expect that Aegerion Pharmaceuticals will post $-0.91 EPS for the current fiscal year.
In other Aegerion Pharmaceuticals news, CEO Marc D. Beer bought 10,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, May 27th. The stock was purchased at an average price of $31.59 per share, with a total value of $315,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.